Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation — Tze‐Fan Chao (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation
Shared by
Professor Gregory Lip
University of Liverpool
Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation
Article
2021
en
Authors
+5 more
TC
Tze‐Fan Chao
YC
Yi‐Hsin Chan
CC
Chern-En Chiang
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2020
Continuation or discontinuation of oral anticoagulants after an increase in HAS-BLED scores and the risks of clinical outcomes in patients with atrial fibrillation. a nationwide cohort study
Tze‐Fan Chao
,
Jo‐Nan Liao
,
Professor Gregory Lip
,
S.A Chen
Article
2017
The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants
Professor Gregory Lip
,
Flemming Skjøth
,
Peter Brønnum Nielsen
,
Jette Nordstrøm Kjældgaard
,
Torben Bjerregaard Larsen
Article
2021
Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer
Daniele Pastori
,
A Marang
,
Arnaud Bisson
,
Julien Herbert
,
Professor Gregory Lip
,
Laurent Fauchier
Article
2017
Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation
Maria Cristina Vedovati
,
Paolo Verdecchia
,
Michela Giustozzi
,
Gabriella Molini
,
Serenella Conti
,
Lucia Pierpaoli
,
Francesca Valecchi
,
Adolfo Aita
,
Giancarlo Agnelli
,
Cecilia Becattini
Article
2017
P4567Predictive value of the HAS-BLED, ATRIA, and ORBIT bleeding risk classification in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants (NOACs)
Peter Brønnum Nielsen
,
F Skjoeth
,
Torben Bjerregaard Larsen
,
Jette Nordstrøm Kjældgaard
,
Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.